Pump thrombosis
| Pump thrombosis | |
|---|---|
| Synonyms | |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Heart failure, shortness of breath, fatigue, chest pain |
| Complications | Stroke, heart attack, device malfunction |
| Onset | |
| Duration | |
| Types | |
| Causes | Blood clot formation in ventricular assist device |
| Risks | Mechanical heart valve, coagulation disorders, inadequate anticoagulation |
| Diagnosis | Echocardiography, blood tests, device interrogation |
| Differential diagnosis | |
| Prevention | Adequate anticoagulation therapy, regular device monitoring |
| Treatment | Anticoagulation, thrombolysis, device replacement |
| Medication | N/A |
| Prognosis | Variable, depending on severity and treatment |
| Frequency | |
| Deaths | |
Pump thrombosis is a serious complication associated with the use of ventricular assist devices (VADs), which are mechanical pumps used to support heart function and blood flow in individuals with weakened hearts. This condition involves the formation of a blood clot within the pump, which can lead to device malfunction and serious clinical consequences.
Pathophysiology[edit]
Pump thrombosis occurs when a thrombus forms within the ventricular assist device. This can obstruct blood flow, leading to increased pump power consumption and potential device failure. The formation of a thrombus is influenced by several factors, including blood flow dynamics, shear stress, and the coagulation cascade.
Risk Factors[edit]
Several risk factors contribute to the development of pump thrombosis:
- Hypercoagulability: Conditions that increase the tendency of blood to clot can predispose patients to pump thrombosis.
- Device-related factors: The design and material of the VAD can influence thrombosis risk. Some devices have higher thrombosis rates due to their design.
- Suboptimal anticoagulation: Inadequate anticoagulation therapy can lead to thrombus formation.
- Patient-related factors: Individual patient characteristics, such as genetic predisposition and comorbidities, can affect thrombosis risk.
Clinical Presentation[edit]
Patients with pump thrombosis may present with:
- Dyspnea
- Fatigue
- Signs of heart failure
- Hemolysis, indicated by elevated lactate dehydrogenase (LDH) levels
- Device alarms indicating increased power consumption
Diagnosis[edit]
The diagnosis of pump thrombosis involves a combination of clinical assessment and diagnostic tests:
- Echocardiography: Used to assess heart function and detect thrombus formation.
- Blood tests: Elevated LDH and plasma-free hemoglobin levels can indicate hemolysis due to pump thrombosis.
- Device interrogation: Analyzing device parameters such as power consumption and flow rates can help identify thrombosis.
Management[edit]
Management of pump thrombosis includes:
- Anticoagulation therapy: Intensifying anticoagulation to prevent further thrombus formation.
- Thrombolysis: Use of thrombolytic agents to dissolve the thrombus.
- Device replacement: In severe cases, surgical replacement of the VAD may be necessary.
Prognosis[edit]
The prognosis of pump thrombosis depends on the timeliness and effectiveness of treatment. Prompt intervention can prevent serious complications such as stroke and heart failure.
Prevention[edit]
Preventive strategies include:
- Optimizing anticoagulation therapy to maintain therapeutic levels.
- Regular monitoring of device function and patient status.
- Use of devices with lower thrombosis risk profiles.
See Also[edit]
Cardiovascular disease A-Z
Most common cardiac diseases
- Cardiac arrhythmia
- Cardiogenetic disorders
- Cardiomegaly
- Cardiomyopathy
- Cardiopulmonary resuscitation
- Chronic rheumatic heart diseases
- Congenital heart defects
- Heart neoplasia
- Ischemic heart diseases
- Pericardial disorders
- Syndromes affecting the heart
- Valvular heart disease
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
A[edit]
- Accelerated idioventricular rhythm
- Acute decompensated heart failure
- Arteriosclerotic heart disease
- Athletic heart syndrome
- Atrial flutter
- Atrioventricular fistula
- Cardiovascular disease in Australia
- Autoimmune heart disease
B[edit]
C[edit]
- Ebb Cade
- Cardiac allograft vasculopathy
- Cardiac amyloidosis
- Cardiac asthma
- Cardiac tamponade
- Cardiogenic shock
- Cardiogeriatrics
- Cardiorenal syndrome
- Cardiotoxicity
- Carditis
- Coronary artery aneurysm
- Coronary artery anomaly
- Coronary artery disease
- Spontaneous coronary artery dissection
- Coronary artery ectasia
- Coronary occlusion
- Coronary steal
- Coronary thrombosis
- Coronary vasospasm
- Cœur en sabot
- Coxsackievirus-induced cardiomyopathy
D[edit]
E[edit]
H[edit]
- Heart attack
- Heart failure
- Heart failure with preserved ejection fraction
- Heart to Heart (1949 film)
- High-output heart failure
- Hyperdynamic precordium
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
I[edit]
- Idiopathic giant-cell myocarditis
- Interventricular dyssynchrony
- Intraventricular dyssynchrony
- Isolated atrial amyloidosis
K[edit]
L[edit]
M[edit]
- Mydicar
- Myocardial bridge
- Myocardial disarray
- Myocardial rupture
- Myocardial scarring
- Myocardial stunning
- Myocarditis
N[edit]
O[edit]
P[edit]
- Papillary fibroelastoma
- Pathophysiology of heart failure
- Postpericardiotomy syndrome
- Pulmonary vein stenosis
R[edit]
S[edit]
- Saturated fat and cardiovascular disease
- SCAR-Fc
- Shone's syndrome
- Strain pattern
- Subacute bacterial endocarditis
- Sudden cardiac death of athletes
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
T[edit]
V[edit]
W[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
